Top 10 Warren Buffett Stocks To Buy Right Now

There are many ways to make money in the stock market. Every investor has their own style, different levels of risk tolerance, and diverse goals. But one of the easiest and most profitable ways to get rich on Wall Street is to follow in the footsteps of true masters such as Warren Buffett and Benjamin Graham.

It’s elementary, really. First, identify companies with fantastic growth opportunities, sustainable business advantages over their rivals, and excellent management teams. Then, buy these stocks at reasonable prices. It’s OK to overpay a bit if you have to. Quality doesn’t always come cheap.

Then, stick those shares under your proverbial pillow and get some undisturbed sleep. Do absolutely nothing for years or even decades. Companies with the qualities I listed a minute ago should be able to deliver solid returns for the long haul, unlocking the magic of compounding returns over very long periods.

Even ardent growth investors with a high tolerance for market risk should have a handful of these surefire long-term bets in their portfolios. For example, my own collection of small-cap tickers, promising growth stocks, and the odd speculative bet is built around a solid core of long-term champions. Whatever happens to the rest of my real-world holdings, I don’t lose a minute of sleep over these proven winners. The stocks mentioned below are firmly established members of that elite group.

Top 10 Warren Buffett Stocks To Buy Right Now: BYD Company Limited (BYDDY)

BYD COMPANY LIMITED is principally engaged in the research, development, manufacture and distribution of automobiles, secondary rechargeable batteries and mobile phone components. The Company operates its businesses primarily through automobile business, which provides automobiles, including G6, S6 and other series; secondary rechargeable battery business, which provides lithium-ion batteries and nickel batteries, which are applied in mobile phones, digital cameras, electric tools, electric toys and other portable electronic devices, as well as mobile phone components and assembly businesses, which offers casings, keypads, liquid crystal display (LCD) modules, cameras, flexible circuit boards, chargers, and mobile phone design and assembly services. The Company operates its business within domestic market and in overseas markets. Advisors’ Opinion:

  • [By ]

    Current subsidies in China were reduced by 20% in 2017 and will be reduced by 40% in 2019 and 100% by 2021. China’s Zero Emission Vehicle (ZEV) credit system was announced on September 28, 2017, and will begin in 2019 with 10% of credits (12% in 2020) required from new energy vehicles (NEVs). That translates to ~4-5% of EV sales as market share for 2019. We also are expecting an announcement at some stage as to when China will ban ICE vehicles, noting BYD (OTCPK:BYDDY) Chairman Wang thinks by 2030. Others think it will be 2035.

  • [By ]

    The pace of consolidations of Chinese rechargeable battery cell companies is accelerating. We made an assertion in our previous report that, with a few exceptions (CATL, BYD), most Chinese names would be consolidated due to the change of subsidy policy by Beijing, and that the industry is likely to become more oligopolistic. It appears that this trend is becoming more pronounced. According to SNE Research, the combined market share of CATL and BYD in the Chinese EV battery market has grown from 43.9% in 2017 to 63.6% in 1H18. China’s subsidies are mostly for high- performance rechargeable batteries, and the NEV credit system, which was implemented this year, is designed to give more credits to companies that use high-performance rechargeable batteries. As such, high-end rechargeable batteries are likely to drive demand, but realistically only CATL and BYD (OTCPK:BYDDY) have the capacity to make these batteries in China.

  • [By ]

    BYD Co., Ltd. (OTCPK:BYDDY) (OTCPK:BYDDF) is the world’s largest manufacturer of EVs (electric vehicles). It is also a major player in e-buses, e-trucks, solar panels, energy storage and batteries. In addition, last year it launched its “Skyrail” transit system. Founder and chairman Wang Chuanfu surprised the markets when he previously announced a planned ten-fold increase in revenues by 2025.

  • [By ]


    2016 August 2016 – EV monthly news begins. The world’s first self-driving taxi service was launched in Singapore, with human drivers as backup. Bloomberg wrote “Why Electric Cars Will Be Here Sooner Than You Think” , and I wrote “Electric Vehicles Will Be Affordable And Popular By 2020 – An EV Portfolio To Consider.” BYD Co’s (OTCPK:BYDDF) (OTCPK:BYDDY) global bus and taxi expansion continues. BYD enters into the monorail business. BYD ends 2016 as global No 1 electric car seller yet again. Lithium saw its price triple in 2016. Global EV sales finished 2016 at 774,000 for the year, up 40% on 2015, and representing 0.85% of the global market share.

    EV costs declining graph

Top 10 Warren Buffett Stocks To Buy Right Now: NRX Pharmaceuticals, Inc.(NRXP)

NRX Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company's pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Advisors’ Opinion:

  • [By Keith Speights (TMFFishBiz)]

    Shares of NRx Pharmaceuticals (NASDAQ:NRXP) jumped 11.8% as of the market close on Wednesday. The big gain came after the company announced positive safety findings from a late-stage study evaluating its drug Zyesami in combination with Gilead Sciences’ Veklury in treating hospitalized patients with acute respiratory failure due to COVID-19.

Top 10 Warren Buffett Stocks To Buy Right Now: Summer Infant Inc.(SUMR)

Summer Infant, Inc., through its subsidiaries, engages in the design, marketing, and distribution of branded juvenile health, safety, and wellness products primarily in North America and the United Kingdom. It offers products in various product categories, including nursery audio/video monitors, safety gates, durable bath products, bed rails, nursery products, booster and potty seats, bouncers, travel accessories, high chairs, swings, feeding products, car seats, and nursery furniture, as well as infant thermometers, related health and safety products, cribs, baby gear, swaddling blankets, and bottles. The company sells its products principally under the Summer Infant, Carter?s, and Disney brand names through mass merchant retailers and specialty retailers, as well as directly to consumers. Summer Infant, Inc. is headquartered in Woonsocket, Rhode Island.

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Summer Infant (SUMR)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Joseph Griffin]

    Summer Infant (NASDAQ:SUMR) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

  • [By Max Byerly]

    News coverage about Summer Infant (NASDAQ:SUMR) has trended somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Summer Infant earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.9918179751106 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Summer Infant (SUMR)

    For more information about research offerings from Zacks Investment Research, visit

Top 10 Warren Buffett Stocks To Buy Right Now: Health Insurance Innovations, Inc.(HIIQ)

Health Insurance Innovations, Inc. operates as a developer, distributor, and administrator of cloud-based individual health and family insurance plans, and supplemental products in the United States. The company offers short-term medical plans that cover individuals for up to 364 days with various co-pay and deductible options; hospital indemnity plans, which provide a daily cash benefit for hospital treatment and doctor office visits, as well as accidental injury and death or dismemberment benefits; and supplemental insurance products comprising pharmacy benefit cards, dental plans, vision plans, and cancer/critical illness plans, as well as deductible and gap protection plans, and life insurance policies. It designs and structures insurance and non-insurance products on behalf of insurance carriers; and markets them to individuals through a network of distributors. Health Insurance Innovations, Inc. was founded in 2008 and is based in Tampa, Florida.

Advisors’ Opinion:

  • [By Stephan Byrd]

    WARNING: “LSV Asset Management Decreases Position in Ennis, Inc. (EBF)” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at

  • [By Logan Wallace]

    These are some of the media stories that may have impacted Accern’s scoring:

    Get Ennis alerts:

    Ennis (EBF) Issues Earnings Results ( Ennis beats by $0.07, beats on revenue ( Ennis up 4% post Q1 results ( Ennis, Inc. Reports Results for the First Quarter Ended May 31, 2018 ( Ennis: Fiscal 1Q Earnings Snapshot (

    Shares of Ennis traded down $0.05, hitting $20.20, during trading on Tuesday, according to The company had a trading volume of 117,000 shares, compared to its average volume of 79,358. The firm has a market cap of $489.94 million, a price-to-earnings ratio of 15.66 and a beta of 0.69. Ennis has a fifty-two week low of $17.65 and a fifty-two week high of $21.50. The company has a quick ratio of 4.63, a current ratio of 5.52 and a debt-to-equity ratio of 0.11.

Top 10 Warren Buffett Stocks To Buy Right Now: GlaxoSmithKline PLC(GSK)

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company’s wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company’s nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has a collaboration agreements with Université de Sherbrooke and Pfizer Inc.; development agreement, and R and D collaboration with Propeller Health; and collaboration and license agreement with Idera pharmaceuticals, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.

Leave a Reply

Your email address will not be published.